Background: Patients with chronic rhinosinusitis with/without nasal polyps (CRSwNP/CRSsNP) benefit from endoscopic sinus surgery (ESS), with an estimated success rate of 80%. At present, the influence on clinical outcome after ESS of eosinophils, eosinophilic mucin (EM), and fungal hyphae (FH) in secretions remains unclear. By delineating CRS groups and subgroups based on the finding of eosinophils, EM, and FH, differences in recurrence after ESS were investigated.
C hronic rhinosinusitis (CRS) is defined as an inflammatory disease of the nose and paranasal sinuses in the presence of symptoms and objective signs for at least 12 weeks without complete resolution. 1 Symptomatic and medical therapy, including long-term antibiotics and local corticosteroids, is essential in CRS management. However, a significant amount of patients are not satisfactorily treated by this conservative approach. There is substantial level II to level III evidence that endoscopic sinus surgery (ESS) is effective in improving symptom score and quality of life in adult patients with CRS. 1 It is important to differentiate between CRS with and without nasal polyps (CRSwNP/CRSsNP), not only because these two entities have their own characteristic pathophysiology, but also regarding the outcome after any treatment, including ESS procedures. The revision rates in CRSsNP patients have been shown to be Ͼ10% and up to 20%. 1 In a retrospective analysis of 123 CRSsNP patients with primary ESS, Smith et al. performed revision surgery in 15% of the cases with a minimum follow-up period of 1 year. 2 Conversely, in a retrospective study of 118 CRSwNP patients with a follow-up ranging from 12 to 168 (median 40 months) months, 71 patients (60%) developed recurrent polyps. 3 In a systematic literature review by Dalziel et al., recurrence of CRSwNP after functional ESS ranged from 4 to 60% with a median of 20%. 4 The aforementioned studies reflect the difference in surgical outcomes after ESS in CRSsNP and CRSwNP patients. These data are particularly important to provide accurate information to the individual patient.
In the last 10 years, research has been directed toward the role of fungi and eosinophilic inflammation in the pathogenesis of upper respiratory tract and middle ear infections, 5 and a classification creating subgroups in CRSsNP and CRSwNP patients was proposed. 6 Subgroups were made based on the presence of eosinophilic tissue infiltration along with the sampling of airway mucus secretions. The latter is important to find eosinophilic mucin (EM) containing necrotic eosinophilic debris and Charcot-Leyden crystals (CLC) and the presence of fungal hyphae (FH). The current study uses this classification as a tool for predicting outcome after ESS. All of our patients treated with complete ESS were analyzed and observed. By delineating CRS groups and subgroups based on the finding of local eosinophils, EM, and FH, we hypothesized to observe differences in the frequency of recurrent disease after ESS over a longer period of time.
METHODS

Study Population
From January 2003 through December 2005, 221 consecutive adult patients (aged Ն18y) who underwent ESS were included in the study. All patients were assessed for symptoms and by nasal endoscopy and computed tomography imaging, to which the EPOS guidelines 1 for diagnosing CRS were applied, and experienced persistent symptoms despite maximal medical treatment. The ESS technique consisted of complete ethmoidectomy, large (if possible) middle meatal maxillary antrostomy, and sphenoidotomy with freeing of the frontal ostium (recess). Postoperative care involved careful endoscopic debridement the day after and 1 week after surgery routinely. Long-term endoscopic care aimed to normalize the nasal cavity mucosa. Saline irrigations were part of the standard protocol. Intranasal steroids were prescribed when persisting mucosal inflammation was noted on endoscopy. Adjunctive antibiotics or oral steroids were added if there was no improvement of the diseased mucosa or if there were patient complaints after 4-6 weeks of treatment with saline and intranasal steroids.
Patients were excluded if surgery was performed to treat antrochoanal polyps, fungus balls, cysts of the paranasal sinuses, and malig- 
Mucosal Tissue and Sinonasal Mucus Secretions
The surgically obtained mucosal tissue was collected and placed in buffered formaldehyde. After embedding in paraffin, it was cut into fine sections and stained with hematoxylin and eosin. Whenever possible, airway mucus secretions with or without attachment to the underlying tissue, were aspirated. Eosinophil counts were considered positive when more than five eosinophils were seen per high power field (ϫ400). 7 When eosinophils were observed, the specimens were further studied for the presence of layers of eosinophils, necrosis, and CLC (debris of dead eosinophils). In the presence of EM in the airway mucus secretions, viz., clusters of eosinophils along with cellular eosinophilic debris and CLC, 5 Gomori methenamine silver staining of the specimens was performed to search for FH. A further differentiation and classification of the fungi was not performed.
Postoperative Evaluation
Recurrence was defined as diseased mucosa (nasal polyps, mucopurulent secretions, and/or inflamed mucosa) assessed by nasal endoscopy, together with three or more bothersome symptoms (nasal blockage, rhinorrhea/postnasal drip, facial pain/headache, smell impairment, and/or sleep disturbance/fatigue) ongoing for at least 1 month, and the need for a systemic treatment (long-term antibiotics or systemic steroids) in that month. 1 Follow-up time was a minimum of 3 years for all patients.
Statistical Analysis
Statistical analysis was performed using SPSS Version 19 (SPSS, Inc., Chicago, IL). Percentages of patient characteristics and subgroups were determined. For between-group comparison, the Mann-Whitney U test and the 2 -/Fisher's exact test were used where appropriate. All tests were two-tailed, and values of p Ͻ 0.05 were considered statistically significant.
RESULTS
Patient Characteristics
Of the 221 included patients, 125 patients suffered from CRSsNP, compared with 96 patients with CRSwNP. Patients' age ranged from 18 to 85 years (mean, 47 years; SD, 15.2 years) and was higher in CRSwNP than in CRSsNP (mean, 50 years; SD, 15.3 years; and mean, 44 years; SD, 14.7 years, respectively). Gender (97 women versus 124 men) was equally distributed between the two groups. Allergy, asthma, and aspirin sensitivity proportions can be found in Table 1 .
Eosinophils in Tissue and Airway Secretions
Eosinophils were present in the mucosal tissue (more than five per high power field; ϫ400) in 57.9% (128/221) of all CRS subjects in our study ( Table 2 ). The CRSsNP group exhibited eosinophilic tissue presence in 42.4% (53/125) versus 78.1% (75/96) in the CRSwNP group (p Ͻ 0.001). Pathological study of mucus airway secretions showed EM presence (eosinophils, CLC, and debris) in 33.9% (75/ 221) of all the CRS patients, again, higher in the CRSwNP group (20.0% versus 52.1%; p Ͻ 0.001). This corresponds to 47.2 and 66.7% of the eosinophil-positive patients with CRSsNP and CRSwNP, respectively (p ϭ 0.027). Hyphae were observed in 6.8% (15/221) of all CRS patients (3.2% in CRSsNP versus 11.5% in CRSwNP; p ϭ 0.028). When only considering EM ϩ patients, hyphae were present in 20.0% (16.0% in CRSsNP versus 22.0% in CRSwNP; p ϭ 0.76). These results are graphically represented in Fig. 1 .
Surgical Outcomes
A global recurrence rate of 22.2% (49/221) was observed over a follow-up period of 3 years. The CRSsNP group showed a global recurrence rate of 8.8% (11/125) versus 39.6% (38/96) in the CRSwNP group (p Ͻ 0.001). When eosinophils were present in the tissue, recurrence occurred in 9.4% (5/53) of the CRSsNP group; this number did not differ from the CRSsNP group without eosinophils. In the eosinophilic CRSwNP group, recurrence occurred in 48.0% (36/75), which was different from the noneosinophilic CRSwNP group (p ϭ 0.002). When tissue eosinophils, EM, and FH were observed in CRSwNP, a recurrence rate of 72.7% (8/11) was found; however, in CRSsNP, no recurrence occurred in the same constellation (0/4). A poor outcome also occurred in the aspirin-sensitive subgroup, with a total recurrence rate of 70.0% (7/10); however, 8/10 aspirin-sensitive subjects belonged to the EM ϩ , FH ϩ CRSwNP group. In Figs. 2 and 3 , the different groups are compared based on recurrence rate.
Interestingly, we also calculated recurrence rates regardless of the CRSsNP/CRSwNP classification. In eosinophil-positive disease, 32.0% (41/128) of the patients experienced relapse of the CRS. In patients with absence of eosinophils in both tissue and sinonasal airway mucus secretions, only 8.6% (8/93) had recurrent disease (p Ͻ 
DISCUSSION
In this long-term observational study on CRS recurrence after ESS, we provide prevalences of different subgroups based on mucus secretion and tissue analysis. Local tissue eosinophilia was present in 78.1% of the CRSwNP patients, but also in 42.4% of the CRSsNP patients. EM could be found in 33.9% and FH in 6.8%, both phenomena occurring more often in CRSwNP compared with CRSsNP. Recurrence seems to differ in these distinct subgroups, with recurrence rates of 22.2% in CRS globally; local tissue eosinophilia and presence of EM were associated with a higher recurrence rate in CRSwNP, but not in CRSsNP. These findings may point to a different role and importance of eosinophils in the two disease entities.
For a long time, fungi have been believed to only play a role in a small subgroup of CRS, viz., allergic fungal rhinosinusitis. Later, some groups overestimated the role of fungal involvement and argued that all CRS would be driven by fungi. 8 Here, we show that EM could be found in about one-third of CRS patients, and FH were present in Ͻ7% of the CRS patients. It was claimed that fungi may be a trigger for eosinophilic inflammation of sinonasal mucosa in CRS patients (with or without nasal polyposis), even in patients who do not have type I hypersensitivity to fungi. 8 This condition was later termed eosinophilic fungal rhinosinusitis (EFRS). 6 Although allergic rhinitis can be present as a comorbid condition, these CRS patients may exhibit EM on histology without evidence for IgE-mediated allergy, which is in line with findings showing that allergy as a comorbidity has no impact on cytokine patterns in CRSwNP. 9 Our findings of Ͻ7% of all CRS with FH do not support a general role for fungi in this disease.
We studied the prevalence of EFRS in a stepwise approach, based on the subclassification of Meltzer et al. 6 First, surgically removed mucosa and sinonasal mucus secretions were tested for eosinophilia. When positive, clusters of eosinophils along with cellular eosinophilic debris and CLC, known as EM, were sought by analyzing the secretions. Ultimately, the specimens were tested for the presence of FH by Gomori methenamine silver staining. In this way, different subdivisions may be distinguished: eosinophilic tissue presence (57.9% in the current study), further eosinophilic airway mucus infiltration characterized by EM features without FH (27.1%, EFRS-like), 5 and eosinophilic airway mucus infiltration characterized by EM features with FH (6.8%, EFRS).
Eosinophilic tissue presence was observed in 57.9% of our patients (78.1% in CRSwNP and 42.4% in CRSsNP). This corresponds with the findings in the European population mentioning 80% of eosinophilic infiltration in nasal polyps 1 and also is in line with findings on the IL-5 expression in European (Belgian) polyps versus Asian CRSwNP. 10 Of interest, 83.7% of the patients with recurrent disease showed eosinophilic involvement. For recurrence after surgery, there is a statistically significant difference between patients with local eosinophilia compared with those without. This association was also observed by Matsuwaki et al., who found the presence of eosinophils in the mucosal tissue to have a positive predictive value of 85.7% for recurrence within 5 years. 11 Preliminary results of Smith et al. suggest that CRS patients with lower eosinophil density are two times more likely to improve with ESS than those with higher eosinophil density. 12 Soler et al. showed that the presence of mucosal tissue eosinophilia at the time of ESS was predictive for less improvement in both disease-specific and general quality of life outcomes compared with patients without mucosal eosinophilia. 13 This effect was observed in their CRSsNP patients but not in their CRSwNP patients. In contrast, our results suggest that eosinophils in CRSsNP do not contribute to recurrence, and even the presence of EM and FH in CRSsNP did not increase the risk for recurrence. However, tissue eosinophils and EM were predictors of recurrence in the CRSwNP group. Methodological differences might explain this discordance. Not only the longer follow-up time and tissue as well as secretion analysis in the current study may contribute to the observed differences, but also the diagnostic cutoff value of tissue eosinophilia may play a role. Evidence for the use of both 5 and 10 eosinophils per high power field has been established and both values are in use. 7, 13, 14 It still has to be unraveled as to which cutoff point is optimal for clinical correlation. This may reduce the differences between similar studies. Nevertheless, tissue eosinophils seem to be an important prognostic factor in CRSwNP, confirming former evidence, and may also contribute to the disease course of CRSsNP. 15 Analysis of the airway mucus secretions enabled us to further subdivide eosinophilic CRS based on the presence of EM with or without FH. It is not unexpected that 52.1% of our CRSwNP patients show EM features to be present in their secretions, probably reflecting the spectrum of eosinophilic inflammation in the sinus mucosa. 10 Concerning recurrence, EM ϩ patients are significantly more prone than their EM Ϫ counterparts, confirming the idea that EM reflects a stronger eosinophilic mucosal disease. In line with these thoughts, 8/10 patients with aspirin sensitivity did show EM features, and aspirin-sensitive patients reached a recurrence rate of 70%. The role of FH in this classification remains unclear; their presence is related to EM features, but FH as a single marker does not seem to further increase the risk of recurrence in a statistically significant way. In CRSsNP, neither EM nor FH had an impact on the recurrence rate.
The duration of clinical observation after ESS varies widely, making it difficult to compare studies and to advise the patient regarding long-term outcome after surgery. 1 Several studies suggest that symptom scores and the endoscopic image do not significantly change anymore after 6-18 months compared with a longer follow-up time. 16 ,17 A 6-month postoperative time frame could be considered an appropriate primary end point after ESS. 18 However, in follow-up studies, we believe recurrent disease should be determined and evaluated only at long-term monitoring as in our study (minimum of 3 years). As proposed in the most recent EPOS article, the assessment of recurrence was based on a combination of nasal endoscopy, patients' symptomatology, and the need for systemic treatment. 1 There are several shortcomings of this study, which was based on a private practice setting rather than a University hospital setting. Eosinophils in the mucosa and the airways were not quantified and thus can not be correlated. No other markers of eosinophilic activation such as eosinophil cationic protein were used, and FH were not further grown and analyzed because of practicability reasons. The current study might underestimate the true prevalence of fungi in this series as novel techniques, e.g., inoculation with trypsin, have been proposed to increase fungal detection sensitivity. 19 Furthermore, no IgE measurements in serum were performed to diagnose allergic fungal rhinosinusitis, and other possible factors with impact on the prognosis such as Staphylococcus aureus enterotoxins were not monitored. Still, we feel that this approach is of value for the private practice setting and merits attention and possibly amelioration in the near future.
By accurate pathological analysis, we could show that a poor outcome after ESS may be expected when eosinophilic tissue infiltration is present. Consequently, it is possible to inform patients of the likely outcome within no more than 1 week after ESS. Based on the specific group and subgroup, determining this likely outcome, clinicians may switch to a more intense postoperative medical management to reduce recurrence rates. Long-term follow-up after ESS highlights the importance of careful postoperative endoscopic control and management showing overall symptom improvement. 16 In CRSwNP, it has been shown that high-dose topical steroids may reduce the need for surgery, 20 and that treatment with systemic steroids may have an impact on the expression of inflammatory markers, such as eosinophilia, 21 and may lead to healthier looking cavities after 6 months of follow-up. 17 
CONCLUSIONS
Accurate prediction of the outcome after ESS in CRSwNP patients requires careful pathological analysis, in which both the mucosal tissue and the airway mucus secretions could be involved. Despite expert surgical care the presence of tissue eosinophils, specifically the presence of EM as a sign of a more severe eosinophilic disease, undermines clinical outcome and therefore implicates a more aggressive and probably prolonged follow-up of postoperative medical management. In contrast, FH were only present in a subgroup of subjects and did not add significantly to the risk of recurrence. 
